Intellia Therapeutics Inc
NTLA9.520USD
-2.800-22.73%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
985.70MMarket Cap
LossP/E TTM
More Details of Intellia Therapeutics Inc Company
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.
Intellia Therapeutics Inc Info
Ticker SymbolNTLA
Company nameIntellia Therapeutics Inc
IPO dateMay 06, 2016
CEODr. John M. Leonard, M.D.
Number of employees403
Security typeOrdinary Share
Fiscal year-endMay 06
Address40 Erie St Ste 130
CityCAMBRIDGE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02139-4254
Phone18572856200
Websitehttps://www.intelliatx.com/
Ticker SymbolNTLA
IPO dateMay 06, 2016
CEODr. John M. Leonard, M.D.
Company Executives of Intellia Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. John M. Leonard, M.D.
Dr. John M. Leonard, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
893.46K
+10.09%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
119.97K
+500.83%
Ms. Eliana Clark, Ph.D.
Ms. Eliana Clark, Ph.D.
Executive Vice President, Chief Technology Officer
Executive Vice President, Chief Technology Officer
92.38K
-1.09%
Dr. David Lebwohl, M.D.
Dr. David Lebwohl, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
51.64K
+125.03%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
49.72K
+19.18%
Dr. Georgia Keresty, Ph.D.
Dr. Georgia Keresty, Ph.D.
Independent Director
Independent Director
24.15K
+49.55%
Mr. Brian M. Goff
Mr. Brian M. Goff
Independent Director
Independent Director
23.41K
+51.92%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
18.80K
+74.05%
Dr. Jesse Goodman, M.D.
Dr. Jesse Goodman, M.D.
Independent Director
Independent Director
16.62K
-8.51%
Mr. Michael P. Dube
Mr. Michael P. Dube
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
2.65K
-41.39%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. John M. Leonard, M.D.
Dr. John M. Leonard, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
893.46K
+10.09%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
119.97K
+500.83%
Ms. Eliana Clark, Ph.D.
Ms. Eliana Clark, Ph.D.
Executive Vice President, Chief Technology Officer
Executive Vice President, Chief Technology Officer
92.38K
-1.09%
Dr. David Lebwohl, M.D.
Dr. David Lebwohl, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
51.64K
+125.03%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
49.72K
+19.18%
Dr. Georgia Keresty, Ph.D.
Dr. Georgia Keresty, Ph.D.
Independent Director
Independent Director
24.15K
+49.55%
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
No Data
By RegionUSD
Name
Revenue
Proportion
United States
14.24M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
10.29%
The Vanguard Group, Inc.
9.52%
BlackRock Institutional Trust Company, N.A.
6.94%
Two Sigma Investments, LP
3.77%
State Street Investment Management (US)
3.49%
Other
65.99%
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
10.29%
The Vanguard Group, Inc.
9.52%
BlackRock Institutional Trust Company, N.A.
6.94%
Two Sigma Investments, LP
3.77%
State Street Investment Management (US)
3.49%
Other
65.99%
Shareholder Types
Shareholders
Proportion
Investment Advisor
45.92%
Investment Advisor/Hedge Fund
19.79%
Hedge Fund
15.43%
Research Firm
5.09%
Corporation
3.45%
Individual Investor
1.53%
Bank and Trust
0.76%
Pension Fund
0.31%
Sovereign Wealth Fund
0.05%
Other
7.66%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
685
93.42M
80.66%
-27.55M
2025Q2
701
102.48M
98.83%
-16.17M
2025Q1
734
106.27M
102.60%
-9.72M
2024Q4
721
99.85M
96.57%
-1.86M
2024Q3
722
94.22M
92.84%
-2.81M
2024Q2
726
90.26M
93.51%
-7.71M
2024Q1
739
91.00M
94.49%
-893.96K
2023Q4
792
85.05M
91.49%
-3.09M
2023Q3
802
83.74M
94.78%
-6.96M
2023Q2
821
81.86M
93.61%
-7.70M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARK Investment Management LLC
13.02M
12.13%
+6.86K
+0.05%
Jun 30, 2025
The Vanguard Group, Inc.
10.83M
10.09%
+100.14K
+0.93%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.04M
7.49%
-367.46K
-4.37%
Jun 30, 2025
Two Sigma Investments, LP
4.37M
4.07%
+394.37K
+9.92%
Jun 30, 2025
State Street Investment Management (US)
4.04M
3.76%
-470.98K
-10.44%
Jun 30, 2025
Regeneron Pharmaceuticals Inc
3.70M
3.45%
--
--
Jun 30, 2025
Baker Bros. Advisors LP
2.68M
2.49%
+2.03M
+315.40%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.61M
2.43%
+126.05K
+5.08%
Jun 30, 2025
Amova Asset Management Co., Ltd.
2.67M
2.49%
-154.10K
-5.45%
Jun 30, 2025
Morgan Stanley Investment Management Inc. (US)
1.96M
1.82%
+783.72K
+66.91%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
ARK Genomic Revolution ETF
4.33%
WisdomTree BioRevolution Fund
4.13%
Global X Genomics & Biotechnology ETF
1.96%
ARK Innovation ETF
1.82%
Virtus LifeSci Biotech Clinical Trials ETF
1.49%
Invesco Dorsey Wright Healthcare Momentum ETF
1.4%
SPDR S&P Biotech ETF
0.81%
Tema Heart & Health ETF
0.51%
Direxion Daily S&P Biotech Bull 3X Shares
0.43%
Avantis US Small Cap Equity ETF
0.21%
View more
ARK Genomic Revolution ETF
Proportion4.33%
WisdomTree BioRevolution Fund
Proportion4.13%
Global X Genomics & Biotechnology ETF
Proportion1.96%
ARK Innovation ETF
Proportion1.82%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.49%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.4%
SPDR S&P Biotech ETF
Proportion0.81%
Tema Heart & Health ETF
Proportion0.51%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.43%
Avantis US Small Cap Equity ETF
Proportion0.21%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
